Nakom (Carbidopa, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, the neurotransmitter lacking in Parkinson's disease. Carbidopa inhibits the peripheral enzyme aromatic L‑amino acid decarboxylase, preventing levodopa from being metabolized before it reaches the brain, thereby enhancing central dopamine availability.

The appropriate dose of Nakom is individualized by the treating physician based on disease severity, patient age, and response to therapy. Clinicians typically start with a low dose and titrate upward to achieve optimal symptom control while minimizing side effects.

The safety of carbidopa/levodopa in pregnancy and lactation has not been definitively established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Nakom product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Nakom combines levodopa with carbidopa, offering more efficient delivery of dopamine to the brain than levodopa alone, which is rapidly degraded peripherally. Compared with dopamine agonists, it provides stronger symptomatic relief but may have a higher risk of motor complications such as dyskinesia over long‑term use.

Store Nakom tablets at temperatures below 25 °C in their original packaging. Protect them from moisture, excessive heat, and direct sunlight. Do not store in bathrooms or near kitchen appliances that generate steam, as humidity can affect tablet integrity.

Nakom is taken orally with a full glass of water, usually with meals to reduce gastrointestinal upset. Tablets should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare provider. Dosing times are spaced according to the prescriber's schedule.

The most serious adverse events include severe orthostatic hypotension, hallucinations or psychosis, dyskinesia (involuntary movements), and rare occurrences of neuroleptic malignant syndrome. Patients should be monitored for sudden changes in blood pressure, mental status, or abnormal movements and report them promptly.

Nakom is contraindicated in individuals with known hypersensitivity to carbidopa, levodopa, or any excipients. It should also be avoided in patients currently taking non‑selective MAO inhibitors or those who have experienced severe allergic reactions to similar dopaminergic agents. A physician must evaluate suitability before initiation.